Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Junshi Biosciences has partnered with the Institute of Microbiology of the Chinese Academy of Sciences (IMCAS) to co-develop neutralising antibodies for Covid-19 treatment.
The partners have identified multiple neutralising antibodies that could effectively inhibit viral invasion in laboratory assays, which have also undergone animal testing.
Data from preliminary in-vitro and in-vivo studies showed the blocking activity of the antibody strains. Currently, the partners are investigating preclinical toxicology and in-vivo activity.